Lineage Cell Therapeutics Statistics

Total Valuation

TLV:LCTX has a market cap or net worth of ILS 725.21 million. The enterprise value is 561.98 million.

Market Cap	725.21M
Enterprise Value	561.98M

Important Dates

The next estimated earnings date is Thursday, August 7, 2025.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	228.36M
Shares Outstanding	n/a
Shares Change (YoY)	+19.97%
Shares Change (QoQ)	-5.89%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	177.74M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	20.38
PB Ratio	2.51
P/TBV Ratio	8.93
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-9.31
EV / Sales	16.94
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-6.61

Financial Position

The company has a current ratio of 3.82, with a Debt / Equity ratio of 0.03.

Current Ratio	3.82
Quick Ratio	3.68
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.10
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -21.75% and return on invested capital (ROIC) is -17.29%.

Return on Equity (ROE)	-21.75%
Return on Assets (ROA)	-12.10%
Return on Invested Capital (ROIC)	-17.29%
Return on Capital Employed (ROCE)	-21.61%
Revenue Per Employee	480,885
Profits Per Employee	-815,447
Employee Count	77
Asset Turnover	0.09
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -10.77% in the last 52 weeks. The beta is 1.52, so TLV:LCTX's price volatility has been higher than the market average.

Beta (5Y)	1.52
52-Week Price Change	-10.77%
50-Day Moving Average	193.46
200-Day Moving Average	232.20
Relative Strength Index (RSI)	71.79
Average Volume (20 Days)	33,821

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	19.36

Income Statement

In the last 12 months, TLV:LCTX had revenue of ILS 35.59 million and -60.34 million in losses. Loss per share was -0.29.

Revenue	35.59M
Gross Profit	-12.16M
Operating Income	-79.39M
Pretax Income	-60.20M
Net Income	-60.34M
EBITDA	-77.17M
EBIT	-79.39M
Loss Per Share	-0.29

Full Income Statement

Balance Sheet

The company has 178.37 million in cash and 8.36 million in debt, giving a net cash position of 170.02 million.

Cash & Cash Equivalents	178.37M
Total Debt	8.36M
Net Cash	170.02M
Net Cash Per Share	n/a
Equity (Book Value)	289.15M
Book Value Per Share	1.29
Working Capital	137.38M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -82.64 million and capital expenditures -2.32 million, giving a free cash flow of -84.97 million.

Operating Cash Flow	-82.64M
Capital Expenditures	-2.32M
Free Cash Flow	-84.97M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is -34.17%, with operating and profit margins of -223.10% and -169.57%.

Gross Margin	-34.17%
Operating Margin	-223.10%
Pretax Margin	-169.16%
Profit Margin	-169.57%
EBITDA Margin	-216.85%
EBIT Margin	-223.10%
FCF Margin	n/a

Dividends & Yields

TLV:LCTX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-19.97%
Shareholder Yield	n/a
Earnings Yield	-8.32%
FCF Yield	-11.72%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TLV:LCTX has an Altman Z-Score of -2.34 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.34
Piotroski F-Score	3